Results of significance testing (p values) comparing withholding therapy versus continuing therapy within DMARD classes
| csDMARD | bDMARD | tsDMARD | |
| Detectable SARS-CoV2 IgG Abs* | |||
| Post first vaccine dose | 0.031 | 0.274 | 0.001 |
| Post second vaccine dose | 0.510 | 0.285 | 0.111 |
| Mean SARS-CoV2 IgG Ab titre† | |||
| Post first vaccine dose | 0.018 | 0.706 | 0.000 |
| Post second vaccine dose | 0.620 | 0.231 | 0.001 |
*Using Fisher’s exact test with significance cut-off 5%.
†Using Kruskal-Wallis test among the immunosuppression groups only with significance cut-off 5%.
Ab, antibody; bDMARD, biologic DMARD; csDMARD, conventional synthetic DMARD; DMARD, disease-modifying antirheumatic drug; tsDMARD, targeted synthetic DMARD.